Third Arc Bio is engineering the arc towards cure for solid tumors and I&I diseases.
Investors 1
Funding Rounds 1
| Date | Series | Amount | Investors |
| 26.07.2024 | Series A | $165M | - |
Mentions in press and media 7
| Date | Title | Description |
| 26.07.2024 | The Week’s 10 Biggest Funding Rounds: Space Tech Startup Astranis Tops List | 5 Shares Email Facebook Twitter LinkedIn
Want to keep track of the largest startup funding deals in 2024 with our curated list of $100 million-plus venture deals to U.S.-based companies? Check out The Crunchbase Megadeals Board.
This is a w... |
| 26.07.2024 | Third Arc Bio Raises $165 Million To Develop Multifunctional Antibodies Optimized For T Cell Engagement | Third Arc Bio – a biotech company developing multifunctional antibodies that are optimized for best-in-class T cell engagement across solid tumors and inflammatory & immunology (I&I) disease – announced a $165 million oversubscribed... |
| 25.07.2024 | Canadian Startups Surge: Clio and Third Arc Bio Lead the Charge**
** | ** In the world of startups, the spotlight often shines brightest on Silicon Valley. Yet, this week, Canadian startups have taken center stage, proving that innovation knows no borders. Two companies, Clio and Third Arc Bio, have made headl... |
| 23.07.2024 | Third Arc Bio Launches with Oversubscribed $165 Million Series A Financing to Deliver Superior Biologics for Solid Tumors and Inflammatory & Immunology (I&I) Diseases | -- Company formed and originally seeded by Omega Funds, Series A financing with exceptional syndicate led by Vida Ventures
-- World-class leadership team led by Peter F. Lebowitz, MD, PhD, Sanjaya Singh, PhD, and Joe Erhardt, PhD, well-posi... |
| 23.07.2024 | Third Arc Bio Launches with $165M Series A Financing | Third Arc Bio, a Boston, MA-based biotech company developing multifunctional antibodies, raised $165M in Series A funding.
The round was led by Vida Ventures and Cormorant Asset Management and Hillhouse Investment. Omega Funds continued als... |
| 23.07.2024 | Third Arc Bio launches with $165M to address unmet needs in oncology and autoimmunity | The company was founded by executives from Johnson & Johnson
Third Arc Bio is a company that says its on mission to deliver transformational therapies for solid tumors and inflammatory & immunology diseases through the use of multif... |
| - | Third Arc Bio | “Third Arc Bio is engineering the arc towards cure for solid tumors and I&I diseases.” |
Reviews 0
